MedTrace Logo

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

NCT05652673 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-02-28

No results posted yet for this study

Summary

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Conditions

  • Melanoma Stage IV
  • Melanoma Stage III
  • Immunotherapy
  • Toxicity, Drug

Interventions

DRUG

nivolumab

Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-12-01
Completion
2029-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652673 on ClinicalTrials.gov